|
|
|
By Sarah Boynton, Quality Executive Partners | This article explores how to create, review, and train on SOPs, as well as how manufacturing and quality teams can collaborate to improve oversight, all with human error prevention in mind. |
|
|
|
Regarding vendor selection in support of allogeneic CAR-T therapy specifically, Gregory Opiteck, Ph.D., VP head of translational sciences at Allogene Therapeutics, covers top challenges, best practices, and expectations for the short term. |
|
|
|
|
| Top 6 Tips To Speed Up Manufacturing Your Product | Article | OmniaBio | Managing the manufacturing process for cell and gene therapy products can be a significant challenge. Delays can affect capacity, resource planning, and the path to product commercialization. |
|
|
|
| Combining Gene Therapies, Carrier Systems, And Medical Devices | Article | By Stefanie Johns, Ph.D., Kymanox Corporation | Drug delivery is one of the most significant obstacles to advancing gene therapies. Examine the opportunities for success in combining novel medical devices to improve delivery of gene therapies. |
|
|
| Challenges Of Scaling Up Cell Therapy To New Geographies | Article | EVERSANA | Cell therapy has emerged as one of the most promising disruptive innovations in the pharma industry, but companies developing cell therapies have not been able to take full advantage of its massive potential. |
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
